Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al. (English)
- New search for: Bertelli, G.
- New search for: Quinton, A. E.
- New search for: Lewis, P. D.
- New search for: Ali, P.
- New search for: Morgan, C.
- New search for: Bertelli, G.
- New search for: Quinton, A. E.
- New search for: Lewis, P. D.
- New search for: Ali, P.
- New search for: Morgan, C.
In:
ANNALS OF ONCOLOGY
;
26
, 1
;
249-250
;
2015
-
ISSN:
- Article (Journal) / Print
-
Title:Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.
-
Contributors:Bertelli, G. ( author ) / Quinton, A. E. ( author ) / Lewis, P. D. ( author ) / Ali, P. ( author ) / Morgan, C. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 26, 1 ; 249-250
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2015-01-01
-
Size:2 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 26, Issue 1
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
thanks to referees 2014| 2015
- 7
-
Phase I trials in oncology: a new era has startedPostel-Vinay, S. / Soria, J. C. et al. | 2015
- 9
-
Challenges in combining novel molecularly targeted agents in cancer medicineYap, T. A. et al. | 2015
- 11
-
Pushing the boundaries of somatic copy-number variation detection: advances and challengesSathirapongsasuti, J. F. et al. | 2015
- 13
-
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trialsSorich, M. J. / Wiese, M. D. / Rowland, A. / Kichenadasse, G. / McKinnon, R. A. / Karapetis, C. S. et al. | 2015
- 21
-
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)†Maschmeyer, G. / Carratalà, J. / Buchheidt, D. / Hamprecht, A. / Heussel, C. P. / Kahl, C. / Lorenz, J. / Neumann, S. / Rieger, C. / Ruhnke, M. et al. | 2015
- 33
-
Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevanceKhoja, L. / Lorigan, P. / Dive, C. / Keilholz, U. / Fusi, A. et al. | 2015
- 40
-
Immune biomarkers of anti-EGFR monoclonal antibody therapyTrivedi, S. / Concha-Benavente, F. / Srivastava, R. M. / Jie, H. B. / Gibson, S. P. / Schmitt, N. C. / Ferris, R. L. et al. | 2015
- 47
-
Estimates of benefits and harms of prophylactic use of aspirin in the general populationCuzick, J. / Thorat, M. A. / Bosetti, C. / Brown, P. H. / Burn, J. / Cook, N. R. / Ford, L. G. / Jacobs, E. J. / Jankowski, J. A. / La Vecchia, C. et al. | 2015
- 58
-
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsTolcher, A. W. / Bendell, J. C. / Papadopoulos, K. P. / Burris, H. A. / Patnaik, A. / Jones, S. F. / Rasco, D. / Cox, D. S. / Durante, M. / Bellew, K. M. et al. | 2015
- 64
-
Sequenza: allele-specific copy number and mutation profiles from tumor sequencing dataFavero, F. / Joshi, T. / Marquard, A. M. / Birkbak, N. J. / Krzystanek, M. / Li, Q. / Szallasi, Z. / Eklund, A. C. et al. | 2015
- 70
-
Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDERSun, Z. / Prat, A. / Cheang, M. C. / Gelber, R. D. / Perou, C. M. et al. | 2015
- 75
-
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapySheri, A. / Smith, I. E. / Johnston, S. R. / A'Hern, R. / Nerurkar, A. / Jones, R. L. / Hills, M. / Detre, S. / Pinder, S. E. / Symmans, W. F. et al. | 2015
- 81
-
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survivalTobin, N. P. / Harrell, J. C. / Lövrot, J. / Egyhazi Brage, S. / Frostvik Stolt, M. / Carlsson, L. / Einbeigi, Z. / Linderholm, B. / Loman, N. / Malmberg, M. et al. | 2015
- 89
-
Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancerCao, K. I. / Lebas, N. / Gerber, S. / Levy, C. / Le Scodan, R. / Bourgier, C. / Pierga, J. Y. / Gobillion, A. / Savignoni, A. / Kirova, Y. M. et al. | 2015
- 95
-
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy†Lindner, J. L. / Loibl, S. / Denkert, C. / Ataseven, B. / Fasching, P. A. / Pfitzner, B. M. / Gerber, B. / Gade, S. / Darb-Esfahani, S. / Sinn, B. V. et al. | 2015
- 101
-
Obesity and the outcome of young breast cancer patients in the UK: the POSH studyCopson, E. R. / Cutress, R. I. / Maishman, T. / Eccles, B. K. / Gerty, S. / Stanton, L. / Altman, D. G. / Durcan, L. / Wong, C. / Simmonds, P. D. et al. | 2015
- 113
-
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†Krop, I. E. / Lin, N. U. / Blackwell, K. / Guardino, E. / Huober, J. / Lu, M. / Miles, D. / Samant, M. / Welslau, M. / Diéras, V. et al. | 2015
- 120
-
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerTreilleux, I. / Arnedos, M. / Cropet, C. / Wang, Q. / Ferrero, J. M. / Abadie-Lacourtoisie, S. / Levy, C. / Legouffe, E. / Lortholary, A. / Pujade-Lauraine, E. et al. | 2015
- 126
-
Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial†Klingbiel, D. / Saridaki, Z. / Roth, A. D. / Bosman, F. T. / Delorenzi, M. / Tejpar, S. et al. | 2015
- 132
-
Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trialÉlez, E. / Kocáková, I. / Höhler, T. / Martens, U. M. / Bokemeyer, C. / Van Cutsem, E. / Melichar, B. / Smakal, M. / Csőszi, T. / Topuzov, E. et al. | 2015
- 141
-
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancerYamada, Y. / Higuchi, K. / Nishikawa, K. / Gotoh, M. / Fuse, N. / Sugimoto, N. / Nishina, T. / Amagai, K. / Chin, K. / Niwa, Y. et al. | 2015
- 149
-
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II studyVan Cutsem, E. / Boni, C. / Tabernero, J. / Massuti, B. / Middleton, G. / Dane, F. / Reichardt, P. / Pimentel, F. L. / Cohn, A. / Follana, P. et al. | 2015
- 156
-
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growthKobayashi, Y. / Mitsudomi, T. / Sakao, Y. / Yatabe, Y. et al. | 2015
- 161
-
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencingSun, J. M. / Choi, Y. L. / Ji, J. H. / Ahn, J. S. / Kim, K. M. / Han, J. / Ahn, M. J. / Park, K. et al. | 2015
- 167
-
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study†Necchi, A. / Mariani, L. / Di Nicola, M. / Lo Vullo, S. / Nicolai, N. / Giannatempo, P. / Raggi, D. / Farè, E. / Magni, M. / Piva, L. et al. | 2015
- 173
-
Renal impairment and late toxicity in germ-cell cancer survivorsLauritsen, J. / Mortensen, M. S. / Kier, M. G. / Christensen, I. J. / Agerbaek, M. / Gupta, R. / Daugaard, G. et al. | 2015
- 179
-
Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trialCella, D. / Ivanescu, C. / Holmstrom, S. / Bui, C. N. / Spalding, J. / Fizazi, K. et al. | 2015
- 185
-
Differences among young adults, adults and elderly chronic myeloid leukemia patientsCastagnetti, F. / Gugliotta, G. / Baccarani, M. / Breccia, M. / Specchia, G. / Levato, L. / Abruzzese, E. / Rossi, G. / Iurlo, A. / Martino, B. et al. | 2015
- 193
-
90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomasBouabdallah, K. / Furst, S. / Asselineau, J. / Chevalier, P. / Tournilhac, O. / Ceballos, P. / Vigouroux, S. / Tabrizi, R. / Doussau, A. / Bouabdallah, R. et al. | 2015
- 198
-
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decadesDas, L. C. / Karrison, T. G. / Witt, M. E. / Muller, C. / Stenson, K. / Blair, E. A. / Cohen, E. E. / Seiwert, T. Y. / Haraf, D. J. / Vokes, E. E. et al. | 2015
- 205
-
A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinomaChen, Y. P. / Wang, Z. X. / Chen, L. / Liu, X. / Tang, L. L. / Mao, Y. P. / Li, W. F. / Lin, A. H. / Sun, Y. / Ma, J. et al. | 2015
- 211
-
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agencyMaeda, H. / Kurokawa, T. et al. | 2015
- 217
-
Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?Gioulbasanis, I. / Martin, L. / Baracos, V. E. / Thézénas, S. / Koinis, F. / Senesse, P. et al. | 2015
- 221
-
Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort†Wang, A. / Kubo, J. / Luo, J. / Desai, M. / Hedlin, H. / Henderson, M. / Chlebowski, R. / Tindle, H. / Chen, C. / Gomez, S. et al. | 2015
- 231
-
Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapyBylicki, O. / Gan, H. K. / Joly, F. / Maillet, D. / You, B. / Péron, J. et al. | 2015
- 238
-
Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategiesIlie, M. I. / Bence, C. / Hofman, V. / Long-Mira, E. / Butori, C. / Bouhlel, L. / Lalvée, S. / Mouroux, J. / Poudenx, M. / Otto, J. et al. | 2015
- 245
-
Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?Abali, H. / Yavuz, S. / Calıkusu, Z. / Seyrek, E. et al. | 2015
- 245
-
Reply to the Letter to the Editor ‘Is fluoropyrimidindes without oxaliplatin optimal for the adjuvant treatment of mainstream stage III colon cancer?’ by Abali et al.Sugihara, K. / Yoshida, M. / Ishiguro, M. et al. | 2015
- 246
-
A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenibRechsteiner, M. / Wild, P. / Kiessling, M. K. / Bohnert, A. / Zhong, Q. / Stahel, R. A. / Moch, H. / Curioni-Fontecedro, A. et al. | 2015
- 248
-
Pharmacokinetic interaction involving fenofibrate and everolimusMir, O. / Poinsignon, V. / Arnedos, M. / Delaloge, S. / Paci, A. et al. | 2015
- 249
-
Reply to the letter to the editor ‘Measured and estimated glomerular filtration rate for carboplatin dose calculation’ by Cathomas et al.Bertelli, G. / Quinton, A. E. / Lewis, P. D. / Ali, P. / Morgan, C. et al. | 2015
- 250
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Diwakar et al.Schilling, B. / Sondermann, W. / Griewank, K. G. / Livingstone, E. / Zimmer, L. / Hillen, U. / Schadendorf, D. et al. | 2015
- 251
-
Reply to the letters to the editor ‘Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma’ by Schilling et al.Davar, D. / Choi, T. / Kirkwood, J. M. et al. | 2015
- 252
-
Letter to the editor concerning ‘Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies’Hassan, W. A. / Bjerre, M. / Hjortebjerg, R. / Magnusson, N. E. / Ramshanker, N. / Frystyk, J. et al. | 2015
- 254
-
P–0271 Concurrent oral UFT and pelvic irradiation as neoadjuvant chemoradiation for operable rectal cancer: a phase II studyHelmy, S. / Abo-Zeid, A. A. / Gado, N. M. / Salman, M. I. / Bassyoni, M. M. / Abd Al Samee, A. / Salem, D. A. et al. | 2015